TG Therapeutics Company Profile (NASDAQ:TGTX)

About TG Therapeutics (NASDAQ:TGTX)

TG Therapeutics logoTG Therapeutics, Inc. (TG) is a biopharmaceutical company focused on the acquisition, development and commercialization of treatments for B-cell malignancies and autoimmune diseases. As of December 31, 2016, the Company was developing two therapies targeting hematological malignancies. TG-1101 (ublituximab) is a glycoengineered monoclonal antibody that targets a specific epitope on the cluster of differentiation (CD20) antigen found on mature B-lymphocytes. The Company is also developing TGR-1202, an orally available Phosphoinositide 3-kinase (PI3K) delta inhibitor. Both TG-1101 and TGR-1202 are in clinical development for patients with hematologic malignancies. The Company also has pre-clinical programs focusing on developing interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitors and anti- programmed cell death ligand 1 (PD-L1) and anti- glucocorticoid-induced tumor necrosis factor receptor (GITR) antibodies.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Symbol: NASDAQ:TGTX
  • CUSIP: N/A
  • Web: www.tgtherapeutics.com
Capitalization:
  • Market Cap: $733.71 million
  • Outstanding Shares: 61,656,000
Average Prices:
  • 50 Day Moving Avg: $10.87
  • 200 Day Moving Avg: $7.66
  • 52 Week Range: $4.10 - $15.05
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -7.21
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $152,381.00
  • Price / Sales: 4,814.95
  • Book Value: $1.64 per share
  • Price / Book: 7.26
Profitability:
  • EBIDTA: ($92,570,000.00)
  • Net Margins: -47,494.08%
  • Return on Equity: -83.18%
  • Return on Assets: -70.72%
Debt:
  • Current Ratio: 4.23%
  • Quick Ratio: 4.23%
Misc:
  • Average Volume: 2.60 million shs.
  • Beta: 2.1
  • Short Ratio: 1.95
 

Frequently Asked Questions for TG Therapeutics (NASDAQ:TGTX)

What is TG Therapeutics' stock symbol?

TG Therapeutics trades on the NASDAQ under the ticker symbol "TGTX."

How were TG Therapeutics' earnings last quarter?

TG Therapeutics Inc (NASDAQ:TGTX) released its quarterly earnings results on Friday, May, 5th. The company reported ($0.52) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.42) by $0.10. The firm had revenue of $0.04 million for the quarter, compared to the consensus estimate of $0.04 million. TG Therapeutics had a negative net margin of 47,494.08% and a negative return on equity of 83.18%. View TG Therapeutics' Earnings History.

Where is TG Therapeutics' stock going? Where will TG Therapeutics' stock price be in 2017?

10 brokerages have issued 12-month price targets for TG Therapeutics' shares. Their forecasts range from $6.40 to $33.00. On average, they anticipate TG Therapeutics' share price to reach $24.84 in the next year. View Analyst Ratings for TG Therapeutics.

What are analysts saying about TG Therapeutics stock?

Here are some recent quotes from research analysts about TG Therapeutics stock:

  • 1. According to Zacks Investment Research, "TG Therapeutics, Inc. is a biopharmaceutical company focused on the acquisition, development and commercialization of pharmaceutical products for the treatment of cancer and other underserved therapeutic needs. The Company is focused on the development of a monoclonal antibody for the treatment of various B-cell proliferative disorders including lymphoma, leukemia, and auto-immune diseases. TG Therapeutics, Inc., formerly known as Manhattan Pharmaceuticals, Inc., is based in New York. " (5/16/2017)
  • 2. FBR & Co analysts commented, "On the morning of March 6, TG Therapeutics announced positive top-line data from its Phase III GENUINE study of TG-1101 (ublituximab) plus ibrutinib in patients with previously treated high-risk chronic lymphocytic leukemia (CLL). The study met its primary endpoint, with an overall response rate (ORR) of 80% in the combination of TG-1101 plus ibrutinib compared to ibrutinib alone in treated patients. The GENUINE Phase III study is a randomized, open-label multi-center trial that is being conducted to evaluate the safety and efficacy of TG-1101 plus ibrutinib compared to ibrutinib alone that has enrolled 126 adult patients with high-risk CLL across 160 clinical sites in the U.S. and Israel. In the study, high risk was defined as patients with one or more of the following: 17p deletion, 11q deletion, or p53 mutation. We believe the top-line data from the study are highly compelling and look forward to the full data set, which the company is targeting to present at a medical meeting in 1H17. The company plans to meet with the FDA to discuss the results and filing for accelerated approval in 2H17." (3/6/2017)

Who are some of TG Therapeutics' key competitors?

Who owns TG Therapeutics stock?

TG Therapeutics' stock is owned by many different of institutional and retail investors. Top institutional shareholders include FMR LLC (11.36%), Vanguard Group Inc. (3.15%), UBS Asset Management Americas Inc. (2.71%), Jennison Associates LLC (2.42%), Columbus Circle Investors (1.77%) and RA Capital Management LLC (1.23%). Company insiders that own TG Therapeutics stock include Laurence N Charney, Sean A Power and William James Kennedy. View Institutional Ownership Trends for TG Therapeutics.

Who sold TG Therapeutics stock? Who is selling TG Therapeutics stock?

TG Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including RA Capital Management LLC, Wells Fargo & Company MN, Nationwide Fund Advisors, Schwab Charles Investment Management Inc., Stoneridge Investment Partners LLC, Morgan Stanley, California Public Employees Retirement System and TIAA CREF Investment Management LLC. Company insiders that have sold TG Therapeutics stock in the last year include Laurence N Charney, Sean A Power and William James Kennedy. View Insider Buying and Selling for TG Therapeutics.

Who bought TG Therapeutics stock? Who is buying TG Therapeutics stock?

TG Therapeutics' stock was purchased by a variety of institutional investors in the last quarter, including FMR LLC, Jennison Associates LLC, EAM Investors LLC, Vanguard Group Inc., Columbus Circle Investors, Kennedy Capital Management Inc., JPMorgan Chase & Co. and Ameriprise Financial Inc.. View Insider Buying and Selling for TG Therapeutics.

How do I buy TG Therapeutics stock?

Shares of TG Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of TG Therapeutics stock cost?

One share of TG Therapeutics stock can currently be purchased for approximately $11.90.

Analyst Ratings

Consensus Ratings for TG Therapeutics (NASDAQ:TGTX) (?)
Ratings Breakdown: 10 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $24.84 (108.74% upside)

Analysts' Ratings History for TG Therapeutics (NASDAQ:TGTX)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
5/18/2017FBR & CoReiterated RatingBuyLowView Rating Details
4/25/2017Jefferies Group LLCInitiated CoverageBuy -> Buy$23.00HighView Rating Details
4/21/2017Raymond James Financial, Inc.Reiterated RatingBuyHighView Rating Details
3/13/2017SunTrust Banks, Inc.Set Price TargetBuy$28.00LowView Rating Details
3/8/2017Ladenburg Thalmann Financial ServicesSet Price TargetBuy$30.00LowView Rating Details
3/7/2017HC WainwrightReiterated RatingBuy$18.00N/AView Rating Details
3/7/2017Langenberg & CompanyBoost Price TargetPositive$28.00 -> $30.00N/AView Rating Details
2/22/2017AegisInitiated CoverageBuy$26.00N/AView Rating Details
12/7/2016Roth CapitalSet Price TargetBuy$33.00N/AView Rating Details
10/6/2016Brean CapitalReiterated RatingBuy$28.00N/AView Rating Details
8/24/2016S&P Equity ResearchLower Price Target$7.15 -> $6.40N/AView Rating Details
6/20/2015MLV & Co.Set Price TargetBuy$22.00N/AView Rating Details
(Data available from 5/26/2015 forward)

Earnings

Earnings History for TG Therapeutics (NASDAQ:TGTX)
Earnings by Quarter for TG Therapeutics (NASDAQ:TGTX)
Earnings History by Quarter for TG Therapeutics (NASDAQ:TGTX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/5/2017Q1 2017($0.42)($0.52)$0.04 million$0.04 millionViewN/AView Earnings Details
11/7/2016Q3($0.31)($0.50)$0.04 million$0.04 millionViewListenView Earnings Details
8/8/2016Q2($0.29)($0.33)$0.04 million$0.04 millionViewN/AView Earnings Details
5/10/2016Q1($0.36)($0.28)$0.04 million$0.04 millionViewListenView Earnings Details
3/7/2016Q4($0.32)($0.37)$38.10 million$38.10 millionViewN/AView Earnings Details
11/9/2015Q3($0.34)($0.28)$0.04 million$0.04 millionViewN/AView Earnings Details
8/10/2015Q215($0.32)($0.38)$0.22 million$0.04 millionViewListenView Earnings Details
5/4/2015Q115($0.33)($0.39)$0.04 million$0.04 millionViewN/AView Earnings Details
3/11/2015Q414($0.26)($0.48)$0.04 million$0.04 millionViewN/AView Earnings Details
11/10/2014Q214($0.32)($0.51)$0.04 million$0.04 millionViewN/AView Earnings Details
7/21/2014($0.28)($0.36)$0.04 million$0.04 millionViewN/AView Earnings Details
5/12/2014Q114($0.19)($0.25)$0.04 million$0.04 millionViewN/AView Earnings Details
3/5/2014Q413($0.18)($0.19)$40.00 million$38.10 millionViewN/AView Earnings Details
11/11/2013Q313($0.22)($0.62)$0.03 million$0.04 millionViewN/AView Earnings Details
8/1/2013Q213($0.16)($0.29)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for TG Therapeutics (NASDAQ:TGTX)
2017 EPS Consensus Estimate: ($1.73)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172($0.48)($0.47)($0.48)
Q2 20172($0.45)($0.41)($0.43)
Q3 20172($0.43)($0.43)($0.43)
Q4 20173($0.44)($0.30)($0.39)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for TG Therapeutics (NASDAQ:TGTX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for TG Therapeutics (NASDAQ:TGTX)
Insider Ownership Percentage: 19.00%
Institutional Ownership Percentage: 50.08%
Insider Trades by Quarter for TG Therapeutics (NASDAQ:TGTX)
Institutional Ownership by Quarter for TG Therapeutics (NASDAQ:TGTX)
Insider Trades by Quarter for TG Therapeutics (NASDAQ:TGTX)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
4/11/2017William James KennedyDirectorSell8,548$10.27$87,787.96View SEC Filing  
4/4/2017Laurence N. CharneyDirectorSell7,000$11.17$78,190.00View SEC Filing  
1/4/2017Sean A. PowerCFOSell8,816$4.55$40,112.80View SEC Filing  
4/18/2016Sean A PowerCFOSell10,000$10.12$101,200.00View SEC Filing  
1/5/2016Sean A PowerCFOSell22,790$11.21$255,475.90View SEC Filing  
7/8/2015William James KennedyDirectorSell17,000$17.08$290,360.00View SEC Filing  
7/1/2015Sean A PowerCFOSell50,054$16.46$823,888.84View SEC Filing  
4/2/2015Sean A PowerCFOSell23,800$15.50$368,900.00View SEC Filing  
1/7/2015Sean A PowerCFOSell66,401$16.40$1,088,976.40View SEC Filing  
1/5/2015Sean A PowerCFOSell54,057$16.40$886,534.80View SEC Filing  
12/16/2014Michael S WeissMajor ShareholderSell210,618$16.44$3,462,559.92View SEC Filing  
12/16/2014Sean A PowerCFOSell38,041$16.44$625,394.04View SEC Filing  
12/11/2013Michael Weissmajor shareholderBuy10,000$3.43$34,300.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for TG Therapeutics (NASDAQ:TGTX)
Latest Headlines for TG Therapeutics (NASDAQ:TGTX)
Source:
DateHeadline
rttnews.com logoMRK's Keytruda Scores Another FDA Nod, NBIX Disappoints, SBPH Achieves It
www.rttnews.com - May 24 at 8:53 AM
streetinsider.com logoTG Therapeutics (TGTX) Reports Positive Outcome from Pre-Planned Interim Analysis by DSMB in UNITY-CLL Phase 3 Trial
www.streetinsider.com - May 23 at 7:36 PM
finance.yahoo.com logoTG Therapeutics Stock Climbs After Successfully Completed Analysis in UNITY-CLL
finance.yahoo.com - May 23 at 7:36 PM
streetinsider.com logoTG Therapeutics (TGTX) Reports Positive Outcome from Pre-Planned Interim Analysis by DSMB in UNITY-CLL Phase 3 ... - StreetInsider.com
www.streetinsider.com - May 23 at 8:54 AM
seekingalpha.com logoTG Therapeutics: Promising MS Data - Seeking Alpha
seekingalpha.com - May 23 at 8:54 AM
finance.yahoo.com logoTG Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : TGTX-US : May 22, 2017
finance.yahoo.com - May 22 at 8:36 AM
globenewswire.com logoTG Therapeutics, Inc. Announces Clinical Data Presentations at the Upcoming 14th International Conference on ... - GlobeNewswire (press release)
globenewswire.com - May 21 at 8:15 AM
americanbankingnews.com logoTG Therapeutics Inc (TGTX) Given Average Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - May 19 at 8:56 PM
americanbankingnews.com logoTG Therapeutics Inc (TGTX) Rating Reiterated by FBR & Co
www.americanbankingnews.com - May 19 at 6:36 PM
finance.yahoo.com logoTG Therapeutics, Inc. Announces Clinical Data Presentations at the Upcoming 14th International Conference on Malignant Lymphoma
finance.yahoo.com - May 19 at 1:08 PM
streetinsider.com logoTG Therapeutics (TGTX) Announces Clinical Data Presentations at EHA
www.streetinsider.com - May 18 at 12:43 PM
finance.yahoo.com logoTG Therapeutics, Inc. Recaps Clinical Data Presentations at the Upcoming 53rd Annual Meeting of the American Society of Clinical Oncology
finance.yahoo.com - May 17 at 8:09 PM
americanbankingnews.com logoTG Therapeutics Inc (TGTX) Downgraded by Zacks Investment Research
www.americanbankingnews.com - May 16 at 12:56 PM
finance.yahoo.com logoETFs with exposure to TG Therapeutics, Inc. : May 15, 2017
finance.yahoo.com - May 16 at 11:58 AM
finance.yahoo.com logoTG Therapeutics, Inc. :TGTX-US: Earnings Analysis: Q1, 2017 By the Numbers : May 12, 2017
finance.yahoo.com - May 12 at 3:41 PM
finance.yahoo.com logoTG Therapeutics, Inc. – Value Analysis (NASDAQ:TGTX) : May 11, 2017
finance.yahoo.com - May 12 at 2:19 AM
finance.yahoo.com logoTG Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : TGTX-US : May 10, 2017
finance.yahoo.com - May 10 at 10:24 AM
americanbankingnews.com logoJefferies Group Weighs in on TG Therapeutics Inc's Q2 2017 Earnings (TGTX)
www.americanbankingnews.com - May 10 at 7:54 AM
americanbankingnews.com logoTG Therapeutics Inc (TGTX) Announces Quarterly Earnings Results
www.americanbankingnews.com - May 8 at 5:26 PM
americanbankingnews.com logoTG Therapeutics Inc (TGTX) Expected to Post Quarterly Sales of $40,000.00
www.americanbankingnews.com - May 5 at 3:32 PM
finance.yahoo.com logoTG Therapeutics, Inc. Provides Business Update and Reports First Quarter 2017 Financial Results
finance.yahoo.com - May 5 at 9:02 AM
finance.yahoo.com logoTG Therapeutics reports 1Q loss
finance.yahoo.com - May 5 at 9:02 AM
americanbankingnews.com logoTG Therapeutics Inc (TGTX) Scheduled to Post Earnings on Friday
www.americanbankingnews.com - May 4 at 10:48 PM
finance.yahoo.com logoTG Therapeutics, Inc. to Host Conference Call on First Quarter 2017 Financial Results and Business Update - Yahoo Finance
finance.yahoo.com - May 3 at 6:25 PM
finance.yahoo.com logoTG Therapeutics, Inc. to Host Conference Call on First Quarter 2017 Financial Results and Business Update
finance.yahoo.com - May 3 at 6:25 PM
americanbankingnews.com logoTG Therapeutics Inc (TGTX) Expected to Post Earnings of -$0.42 Per Share
www.americanbankingnews.com - May 3 at 9:43 AM
americanbankingnews.com logoTG Therapeutics (TGTX) Getting Somewhat Positive Media Coverage, Report Finds
www.americanbankingnews.com - May 2 at 7:04 PM
americanbankingnews.com logoFBR & Co Reiterates Buy Rating for TG Therapeutics Inc (TGTX)
www.americanbankingnews.com - May 1 at 7:36 PM
streetinsider.com logoTG Therapeutics (TGTX) Offers Prelim. Results from Ongoing Phase 2 Study of TG-1101 in Patients with MS at AAN - StreetInsider.com
www.streetinsider.com - April 29 at 3:49 PM
streetinsider.com logoTG Therapeutics (TGTX) Offers Prelim. Results from Ongoing Phase 2 Study of TG-1101 in Patients with MS at AAN
www.streetinsider.com - April 28 at 10:44 PM
finance.yahoo.com logoTG Therapeutics Announces Preliminary Results from Ongoing Phase 2 Study of TG-1101 (ublituximab) in Patients with Multiple Sclerosis at the American Academy of Neurology 69th Annual Meeting
finance.yahoo.com - April 28 at 10:44 PM
americanbankingnews.com logoTG Therapeutics (TGTX) Given Coverage Optimism Score of 0.18
www.americanbankingnews.com - April 28 at 3:33 PM
fool.com logoWhy TG Therapeutics Inc. Jumped Higher Today - Motley Fool
www.fool.com - April 27 at 9:22 PM
americanbankingnews.com logoTG Therapeutics Inc to Post Q1 2017 Earnings of ($0.47) Per Share, Jefferies Group Forecasts (TGTX)
www.americanbankingnews.com - April 27 at 7:27 AM
finance.yahoo.com logoTG Therapeutics, Inc. Recaps Schedule of Data Presentation at the Upcoming American Academy of Neurology 69th ... - Yahoo Finance
finance.yahoo.com - April 26 at 4:41 PM
benzinga.com logoPotential FDA Controversy Brewing For TG Therapeutics? - Benzinga
www.benzinga.com - April 26 at 4:41 PM
finance.yahoo.com logoHarry Boxer’s two infrastructure stocks to watch
finance.yahoo.com - April 26 at 4:41 PM
finance.yahoo.com logoETFs with exposure to TG Therapeutics, Inc. : April 26, 2017
finance.yahoo.com - April 26 at 4:41 PM
finance.yahoo.com logoToday's Research Reports on Stocks to Watch: Teva Pharmaceutical and TG Therapeutics
finance.yahoo.com - April 26 at 8:50 AM
finance.yahoo.com logoWhy TG Therapeutics Inc. Jumped Higher Today
finance.yahoo.com - April 25 at 7:10 PM
feeds.benzinga.com logoPotential FDA Controversy Brewing For TG Therapeutics?
feeds.benzinga.com - April 25 at 12:22 PM
americanbankingnews.com logoTG Therapeutics (TGTX) Earning Positive Media Coverage, Report Shows
www.americanbankingnews.com - April 25 at 11:11 AM
americanbankingnews.com logoJefferies Group LLC Initiates Coverage on TG Therapeutics Inc (TGTX)
www.americanbankingnews.com - April 25 at 9:57 AM
americanbankingnews.com logoTG Therapeutics Inc (TGTX) Receives Consensus Rating of "Buy" from Brokerages
www.americanbankingnews.com - April 24 at 9:40 PM
finance.yahoo.com logoTG Therapeutics, Inc. Recaps Schedule of Data Presentation at the Upcoming American Academy of Neurology 69th Annual Meeting
finance.yahoo.com - April 24 at 10:26 AM
benzinga.com logoPhysician Views Off-Label Use A 'Double-Edged Sword' For TG Therapeutics - Benzinga
www.benzinga.com - April 22 at 7:22 PM
globenewswire.com logoTG Therapeutics, Inc. Announces Clinical Data Presentations at the Upcoming 53rd Annual Meeting of the American ... - GlobeNewswire (press release)
globenewswire.com - April 22 at 7:22 PM
americanbankingnews.com logoTG Therapeutics (TGTX) Given Coverage Optimism Rating of 0.03
www.americanbankingnews.com - April 21 at 10:54 PM
finance.yahoo.com logoPhysician Views Off-Label Use A 'Double-Edged Sword' For TG Therapeutics
finance.yahoo.com - April 21 at 7:58 PM
americanbankingnews.com logoTG Therapeutics' (TGTX) Buy Rating Reiterated at Raymond James Financial, Inc.
www.americanbankingnews.com - April 21 at 6:16 PM

Social

Chart

TG Therapeutics (TGTX) Chart for Friday, May, 26, 2017

This page was last updated on 5/26/2017 by MarketBeat.com Staff